• CLC Urges Senate Action on Health Reform
  (November 18, 2009)

• CLC Endorses S. 1773, Comprehensive Cancer Care Improvement Act
  (October 27, 2009)

• CLC Endorses HR 1844, Comprehensive Cancer Care Improvement Act
  (October 27, 2009)

• CLC Urges Changes in Proposed 2010 Physician Fee Schedule
  (October 19, 2009)

• CLC Identifies Desirable Qualities for NCI Director
  (July 17, 2009)

• CLC Comments on Key Elements of Health Care Reform
  (June 30, 2009)

• CLC Endorses HR 716, Access to Cancer Clinical Trials Act
  (April 28, 2009)

• CLC Endorses S. 488, Access to Cancer Clinical Trials Act
  (April 28, 2009)

• CLC Comments on ALERT Act S 717
  (April 28, 2009)

• CLC Urges COBRA Assistance in Stimulus Package
  (February 11, 2009)

• CLC Urges Clear FEHBP Clinical Trials Policy
  (January 6, 2009)

• CLC Applauds Nomination of Daschle as HHS Secretary
  (January 5, 2009)

• CLC Urges Inclusion of $1.9 Billion for NIH in Stimulus Package
  (November 12, 2008)

• CLC Urges Boost in FY 2009 Appropriations for NIH
  (September 19, 2008)

• CLC Outlines Plan for Cancer Research and Care
  (July 15, 2008)

• CLC Endorses Access to Cancer Clinical Trials Act
  (June 25, 2008)

• CLC Urges FDA to Finalize Regulations on Expanded Access
  (June 25, 2008)

• CLC Submits Comments on NIH Evaluation of Peer Review System
  (March 17, 2008)

• CLC Urges Support of Specter-Harkin Amendment to FY 2009 Budget Resolution
  (March 11, 2008)

• CLC Comments to CMS Re Proposed Decision Memo for Clinical Trial Policy
  (August 17, 2007)

• CLC endorses Comprehensive Cancer Care Improvement Act
  (June 27, 2007)

• CLC Urges Strong Support for Cancer Clinical Research
  (June 20, 2007)

• CLC Submits Comments on Medicare Coverage Proposal for Erthyropoiesis Stimulating Agents
  (June 13, 2007)

• CLC Recommends Revisions of Proposed Rules for Advisory Committee Conflicts of Interest
  (May 29, 2007)

• CLC Comments on Draft Decision Memorandum on Clinical Trials
  (May 9, 2007)

• CLC Comments on Medicare Compendia
  (May 9, 2007)

• CLC Urges Senate Passage of Stem Cell Research Enhancement Act
  (April 10, 2007)

• CLC Submits Comments on Expanded Access Proposal
  (March 20, 2007)

• CLC Urges House Approval of Stem Cell Research Enhancement Act
  (January 9, 2007)

• CLC Comments on CMS Reconsideration of Clinical Trials Policy
  (November 30, 2006)

• CLC Comments on CY 2007 Proposal for Reimbursing Cancer Therapies in Hospital Outpatient Departments
  (October 10, 2006)

• CLC Urges CMS to Retain Medicare Clinical Trials Coverage Policy
  (August 9, 2006)

• CLC Urges Extension in Comment Period on Reconsideration of Medicare Clinical Trials Coverage Policy
  (July 18, 2006)

• Cancer Organizations Urge the Senate to Approve the Stem Cell Research Enhancement Act
  (July 14, 2006)

• CLC Urges Favorable Consideration of Citizen Petition on Expanded Access Programs
  (June 12, 2006)

• CLC Urges House to Increase Budget Allocation for Health Programs
  (May 9, 2006)

• CLC Urges Senate to Reject Small Business Health Plan Legislation
  (May 9, 2006)

• Letter in Support of Specter-Harkin Amendment to Boost Health and Education Allocation
  (March 14, 2006)

• CLC Recommends Standards for Coverage of Anticancer Drugs in CY 2007
  (March 6, 2006)

• CLC Comments on Compendia for Listing of Off-Label Uses of Cancer Drugs
  (February 27, 2006)
  
  
• CLC Comments on Structure and Mission of NCI Translational Research Working Group
  (January 20, 2006)
  
  

• CLC Comments on CDC Draft Research Plan
  (January 13, 2006)

• CLC Recommends Changes in USP Draft Guidelines for Medicare Plans in 2007
  (January 6, 2006)

• CLC Commends Development of NCCN Compendium
  (November 18, 2005)

• CLC Recommends the Appointment of a Permanent FDA Commissioner
  (November 18, 2005)

• CLC Urges Changes in Competitive Acquisition Program
  (September 6, 2005)

• CLC Comments on CMS Proposal on Coverage with Evidence Development
  (June 6, 2005)

• CLC Comments on FDA Guidance on Cancer Endpoints
  (June 3, 2005)

• CLC Applauds FDA Guidance on Central IRB Review
  (May 27, 2005)

• CLC Endorses Stem Cell Research Enhancement Act
  (May 20, 2005)

• CLC Objects to Revised NIH Ethics Rules
  (March 31, 2005)

• CLC Comments on Medicare Coverage of Anti-Emetics
  (February 3, 2005)

• CLC Recommends Development of Guidelines for Fertility Preservation Counseling
  (January 21, 2005)
  
  
• CLC Applauds Medicare Coverage of Smoking Cessation Counseling
  (January 21, 2005)
  
  
• CLC Comments on CY 2005 Physician Fee Schedule
  (December 23, 2004)
  
  
• CLC Urges Broad Coverage of Colorectal Cancer and Other Anticancer Drugs
  (December 23, 2004)
  
  
• CLC Commends CMS Decision to Expand Coverage of PET Scans
  (December 1, 2004)
  
  
• CLC Recommends Prompt Appointment of Director of Oncology Products Office (November 5, 2004)
  
  
• CLC Submits Comments on USP Draft Guidelines for Medicare Part D
  (September 17, 2004)
  
  
• CLC Comments on National Cancer Cooperative Groups' Report on Cancer Clinical Research
  (July 7, 2004)
  
  
• CLC Urges Prompt Release by CMS of Medicare ASP Data
  (July 7, 2004)
  
  
• CLC Urges Coverage of Off-Label Uses of Cancer Drugs in Medicare Demonstration Project
  (April 26, 2004)
  
  
• CLC Endorses McClellan to Head CMS
  (March 5, 2004)
  
  
• CLC Calls for Prompt Implementation of Oral Cancer Demonstration Project
  (March 4, 2004)
  
  
• CLC Urges Medicare Conferees to Approve Oral Drug Coverage
  (November 6, 2003)
  
  
• CLC Commends Senator Hatch for Leadership on Medicare Oral Drug Coverage
  (October 23, 2003)
  
  
• CLC Submits Comments on Proposed Rule on Payment Reform for Part B Drugs
  (October 10, 2003)
  
  
• CLC Submits Comments on Proposed Calendar Year 2004 Update of Hospital Outpatient Prospective Payment System (HOPPS)
  (October 6, 2003)
  
  
• Letter To All Medicare Conferees Urging Oral Cancer Drug Transition Benefit
  (September 24, 2003)
  
  
• Letter to Representatives and Senators Identifying Flaws in Cancer Care Provisions of Medicare Bills
  (July 14, 2003)
  
  
• Letter to Energy & Commerce Committee In Support of Balanced Cancer Care Reform
  (June 18, 2003)
  
  
• Cancer Organizations Express Strong Support for Quality Cancer Care Preservation Act
  (April 7, 2003)
  
  
• CLC Urges CMS to Abandon National Coverage Analysis Process for Cancer Drugs
  (March 14, 2003)
  
  
• CLC Hails Introduction of Access to Cancer Therapies Act in 108th Congress
  (March 13, 2003)
  
  
• CLC Recommends Changes in FDA Review of Cancer Therapies
  (February 24, 2003)
  
  
• CLC Takes Issue with CMS Policy on Medicare Coverage of New Therapies
  (December 16, 2002)
  
  
• Letter to CMS Administrator Scully Urging Changes to Proposed Rule Setting 2003 Outpatient Payment Rates
  (October 8, 2002)
  
  
• Roll Call Ad Urging Congressional Action on Access to Cancer Therapies Act
  (October 8, 2002)
  
  
• Letter to Entire Senate Endorsing Access to Cancer Therapies Act
  (October 7, 2002)
  
  
• CLC Applauds Introduction of Lifespan Respite Care Act of 2002
  (October 4, 2002)
  
  
• Letter to CMS Administrator Scully Re: Urging Assignment of High-Dose IL-2 Therapy to New DRG
  (September 12, 2002)
  
  
• Letter to CMS Administrator Scully Re: Program Memorandum on Self-Administered Drugs
  (July 11, 2002)
  
  
• CLC Urges Pass-Through Payment for New Cancer Drugs
  (May 31, 2002)
  
  
• CLC Urges President Bush to Ensure Fair Medicare Payment for Cancer Care
  (May 23, 2002)
  
  
• CLC Recommends Correction in Payment Rate for Cancer Drugs Used in Hospital Outpatient Setting
  (May 17, 2002)
  
  
• CLC Applauds Senate Committee's Review of Mammography Service Issue
  (May 8, 2002)
  
  
• CLC Endorses Legislation Requiring Coverage of Colorectal Screening Services
  (May 8, 2002)
  
  
• Comments on March 27, 2002 Proposed Rule Re: "The Privacy Rule"
  (April 26, 2002)
  

• CLC Urges Conference Action on Nursing Shortage
  (April 19, 2002)
  
  
• Letter to DEA Administrator Hutchinson Commending Agency Action on Pain Medications
  (February 22, 2002)
  
  
• Letter to Entire Senate (Second Session) Urging Support for Access to Cancer Therapies Act
  (February 21, 2002)
  
  
• Letter to Entire House of Representatives (Second Session) Urging Support for Access to Cancer Therapies Act
  (February 21, 2002)
  
  
• Letter to Tommy Thompson Supporting Continued Coverage of Clinical Trials by Medicare
  (February 11, 2002)
  
  
• Letter to Energy & Commerce, Ways & Means & Finance Committees Re Medicare Reimbursement for Cancer Drugs
  (December 6, 2001)
  
  
• Senior Groups Join CLC in Letter to Congress Endorsing the Access to Cancer Therapies Act
  (November 27, 2001)
  
  
• Letter to All Members of Ways & Means, Energy & Commerce and Senate Finance Committee Regarding Medicare Payment for Physician-Administered Drugs
  (October 19, 2001)
  
  
• Letter to Senators Harkin and Specter Regarding FY 2002 NIH Funding Increase
  (October 4, 2001)
  
  
• Letter to CMS Regarding Hospital Outpatient Prospective Payment System Pass-Through Payments
  (October 3, 2001)
  
  
• Letter to Representative Frank Wolf Urging Balanced Approach to the Regulation of Pain Medications
  (September 19, 2001)
  
  
• Letter to Senator Edward M. Kennedy Urging Balanced Approach to the Regulation of Pain Medications
  (September 19, 2001)
  
  
• Letter to Entire House of Representatives Urging Cosponsorship of Access to Cancer Therapies Act of 2001
  (September 6, 2001)
  
  
• Letter to CMS Administrator Scully Re: Reimbursement for Injectable Drugs
  (August 28, 2001)
  
  
• CLC Endorses Dr. Richard Pazdur for FDA Commissioner
  (July 12, 2001)
  
  
• Letter to Rep. Allen Re: FDA Approval Process
  (July 10, 2001)
  
  
• Letter to Sens. McCain, Kennedy and Edwards Applauding Introduction of Patients' Bill of Rights
  (June 13, 2001)
  
  
• Letter to Senators Urging Co-Sponsorship of the Access to Cancer Therapies Act, S. 913
  (June 12, 2001)
  
  
• Letter to Senate Co-Sponsors Applauding Introduction of the Access to Cancer Therapies Act, S. 913
  (June 12, 2001)
  
  
• Letter to Tommy Thompson Applauding Expeditious Approval of New Cancer Therapy
  (May 31, 2001)
  
  
• Letter to Representative Pryce Applauding Introduction of the Access to Cancer Therapies Act of 2001
  (April 25, 2001)
  
  
• Comments on Medical Records Privacy Regulations
  (March 30, 2001)

• Letter to Representative Pryce Applauding Introduction of the Access to Cancer Clinical Trials Act
  (March 29, 2001)
  
  
• Letter to Tommy Thompson Endorsing Dr. Richard Pazdur for FDA Commissioner
  (January 17, 2001)
  
  

What's New  |  About CLC  |  Policy Issues  |  Participants' Login
Home  |  Sitemap  |  Contact Info

Copyright © 2001-2002 Cancer Leadership Council. All rights reserved.
Please send comments and suggestions to webmaster@cancerleadership.org.